Table 1.
Demographic and clinical characteristics of people living with HIV from CNICS sites across the United States who initiated their first antiretroviral therapy regimen between 2012–2019.
| N (%) or Mean (SD)a | Everyone | EFV | RPV | ATV | DRV | RAL | EVG/TDF | EVG/TAF | DTG/TDF | DTG/TAF | DTG/ABC | BIC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 3232 (100) | 427 (13) | 347 (11) | 97 (3) | 263 (8) | 99 (3) | 787 (24) | 289 (9) | 237 (7) | 127 (4) | 389 (12) | 170 (5) |
| Age (years) | 37 (12) | 37 (11) | 35 (11) | 35 (11) | 38 (11) | 43 (12) | 35 (11) | 35 (12) | 39 (13) | 39 (13) | 38 (13) | 35 (11) |
| Female (N (%)) | 505 (16) | 34 (8) | 61 (18) | 32 (33) | 47 (18) | 22 (22) | 103 (13) | 35 (12) | 44 (19) | 22 (17) | 80 (21) | 25 (15) |
| Race/ethnicity | ||||||||||||
| White (N (%)) | 1136 (35) | 185 (43) | 102 (29) | 41 (42) | 99 (38) | 56 (57) | 273 (35) | 87 (30) | 100 (42) | 43 (34) | 108 (28) | 42 (25) |
| Black (N (%)) | 1463 (45) | 149 (35) | 165 (48) | 46 (47) | 103 (39) | 27 (27) | 374 (48) | 136 (47) | 87 (37) | 60 (47) | 211 (54) | 105 (62) |
| Hispanic (N (%)) | 402 (13) | 67 (16) | 52 (15) | 6 (6) | 44 (17) | 9 (9) | 86 (11) | 43 (15) | 29 (12) | 13 (10) | 43 (11) | 10 (6) |
| Other (N (%)) | 231 (7) | 26 (6) | 28 (8) | 4 (4) | 17 (6) | 7 (7) | 54 (7) | 23 (8) | 21 (9) | 11 (9) | 27 (7) | 13 (8) |
| HCV (N (%)) | 298 (9) | 32 (7) | 25 (7) | 16 (16) | 33 (13) | 22 (22) | 51 (6) | 33 (11) | 26 (11) | 14 (11) | 30 (8) | 16 (9) |
| HBV (N (%)) | 84 (3) | 5 (1) | 10 (3) | 3 (3) | 7 (3) | 3 (3) | 29 (4) | 7 (2) | 10 (4) | 3 (2) | 3 (1) | 4 (2) |
| Nadir CD4 (cells/mm3) | 381 (249) | 400 (245) | 432 (201) | 373 (220) | 295 (232) | 375 (252) | 378 (253) | 425 (273) | 325 (228) | 372 (272) | 388 (255) | 379 (270) |
| Smoker (N (%)) | 633 (20) | 79 (19) | 67 (19) | 28 (29) | 63 (24) | 23 (23) | 139 (18) | 52 (18) | 59 (25) | 41 (32) | 53 (14) | 29 (17) |
| Diabetes (N (%)) | 152 (5) | 19 (4) | 16 (5) | 2 (2) | 11 (4) | 5 (5) | 26 (3) | 11 (4) | 19 (8) | 5 (4) | 30 (8) | 8 (5) |
| Baseline weight (kg) | 79 (19) | 80 (17) | 81 (19) | 80 (18) | 77 (17) | 80 (18) | 79 (18) | 79 (21) | 75 (16) | 80 (18) | 82 (21) | 80 (20) |
| Baseline BMI (kg/m2) | 26 (6) | 26 (5) | 27 (6) | 26 (6) | 25 (5) | 26 (5) | 26 (6) | 26 (7) | 25 (5) | 26 (6) | 27 (7) | 26 (6) |
| Years on regimen (years) | 1.9 (1.6) | 2.2 (1.9) | 2.6 (2.0) | 1.8 (1.8) | 1.9 (1.6) | 2.2 (1.8) | 2.2 (1.6) | 1.6 (1.0) | 1.3 (1.2) | 1.1 (0.8) | 2.1 (1.4) | 0.5 (0.3) |
Definitions: EFV (Efavirenz®), RPV (Edurant®, Complera®, Odefsey®), ATV (Atazanavir®), DRV (Prezista®, Prezcobix®), RAL (Isentress®, Isentress HD®), EVG (Vitekta®, Stribild®, Genvoya®), DTG (Tivicay®, Triumeq®), BIC (Biktarvy®), ABC (abacavir), TDF (tenofovir disoproxil fumarate), TAF (tenofovir alafenamide fumarate)
Abbreviations: HCV: hepatitis C virus; HBV: hepatitis B virus; BMI: body mass index; CNICS: Centers for AIDS Research Network of Integrated Clinical Systems
All tests for differences between regimens tested significant at p<0.05, except HBV (p=0.13)